摘要
目的通过检索人乳头瘤病毒(HPV)疫苗接种人群扩大到男性的卫生经济学相关文献,系统评价其研究质量与结果,为HPV疫苗免疫策略制定提供参考。方法采用系统综述设计,收集2010年1月至2022年9月PubMed、Web of Science、中国知网、万方数据库等数据库发表的包括男性人群接种HPV疫苗的卫生经济学研究文献,根据卫生经济学评价报告标准(2022版)评分(满分28分)评价文献质量,分析卫生经济学评价结果。结果共纳入符合标准的文献21篇,均为国外研究,文献的CHEERS评分平均为25.71分(范围:23~28分)。85.71%(12/14)不分性别的研究结果显示,在一定条件下(年龄在10~15岁青少年或26岁以下成年男性),纳入男性接种比单独女性接种更符合成本效果/效用;80.00%(4/5)单独研究普通男性研究结果认为男性接种HPV疫苗符合成本效果;2篇针对男男性行为(MSM)人群的评价均认为符合成本效果。此外,2篇不分性别研究、1篇针对单独男性研究结果认为扩大至男性接种HPV不符合成本效果/效用,主要原因是疫苗价格高、接种年龄大等。结论HPV疫苗接种扩大到男性人群的卫生经济学评价研究质量较高,针对青少年和年轻男性以及重点人群(如MSM)接种倾向于符合成本效果,其他人群接种还需要进一步评估,建议国内尽快开展相关研究,为HPV接种范围扩大至男性提供依据。
Objective To systematically collect and evaluate the health economics research of Human papilloma virus(HPV)vaccination population expansion to men,and to provide evidence for optimizing HPV vaccine immunization strategies.Methods Health economics research studies on male HPV vaccination published in databases including PubMed,Web of Science,CNKI,and Wanfang Database from January 2010 to September 2022 were collected according to the systematic evaluation research design.The quality of the studies was assessed using the health economics evaluation reporting standards(2022 edition)(CHEERS 2022),with full score of 28.The results of the studies were reviewed and analyzed systematically.Results A total of 21 studies complies with the criteria were included,all of which was foreign research.The average CHEERS score of the literatures was 25.71 points,range from 23 to 28 points.85.71%(12/14)studies of the gender-neutral population showed that including male in HPV vaccination were more consistent with the cost effectiveness than female vaccination alone under certain conditions(target at adolescents of 10 to 15 years old or adults under 26 years old).80.00%(4/5)of the studies target at ordinary men only were proved that male vaccination with HPV vaccine was in line with the cost-effectiveness.2 studies targeting men who have sex with men(MSM)were both concluded that it met the cost-effectiveness.In addition,the results of 2 gender-neutral population studies and 1 study on men alone showed that extending HPV vaccination to men did not conform to cost effectiveness.The main reasons for the non-cost-effectiveness included the high price of vaccines and the age of vaccination.Conclusion The quality of the health economics evaluation studies on expanding HPV vaccination to the male population is high.Vaccination targeting adolescents and young men as well as special groups(such as MSM)are likely to be cost-effective,and vaccinations for other groups are still need further evaluated.It is recommended that relevant research should be conducted to provide evidence for expanding the scope of HPV vaccination to men in China.
作者
苏颖
何寒青
周洋
邓璇
Su Ying;He Hanqing;Zhou Yang;Deng Xuan(School of Public Health,Zhejiang Chinese Medical University,Hangzhou 310053,China;Department of Immunization Program,Zhejiang Provincial Center for Disease Control and Prevention,Hangzhou 310051,China)
出处
《中华预防医学杂志》
CAS
CSCD
北大核心
2023年第11期1869-1877,共9页
Chinese Journal of Preventive Medicine
基金
浙江省哲学社会科学规划课题 (22NDQN298YB)。
